imported_Joe
08-15-2005, 08:40 AM
Latest-generation Leksell Gamma Knife® Offers Enhanced Treatment Options for
Brain Tumors and Disorders
ATLANTA, Aug. 15 /PRNewswire/ -- Radiosurgery is credited with improving
patient quality of life, reducing treatment costs and enhancing clinical
outcomes. Patients undergoing non-invasive Gamma Knife® surgery, which is
completed in a matter of hours, generally go home within 24 hours and resume
normal activities within a few days.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020318/ELEKTALOGO )
More than 220 Gamma Knife® units are in operation worldwide and more
than 350,000 patients have been treated, according to Jim Rose, Vice President
and head of Marketing in North America for Elekta, the system's manufacturer.
"Gamma Knife® surgery remains the most accurate and proven means of
performing brain radiosurgery, and the single most trusted and utilized
solution for treating intracranial disorders without invasive surgery," he
said.
Cedars-Sinai Medical Center, which has been voted the most preferred
hospital in Los Angeles for all health needs for the past 17 years, will soon
add Leksell Gamma Knife® 4C to its Samuel Oschin Comprehensive Cancer
Institute.
This latest-generation system offers a simplified and more efficient
treatment process and enhanced precision through new, integrated image
treatment possibilities. It includes Leksell GammaPlan® 4C planning
software, providing users with a previously unattainable possibility to
integrate images from various image sources and as a result achieve higher
treatment precision and improved treatment results.
"We continually seek more effective means of treating brain tumors," said
Keith L. Black, M.D., Director of the Cedars-Sinai Maxine Dunitz Neurosurgical
Institute and Director of the medical center's Division of Neurosurgery and
Comprehensive Brain Tumor Program. "The efficacy of Gamma Knife® surgery,
documented in over 2,000 peer-reviewed published papers, makes this an
excellent complement to our existing therapies and radiosurgery capabilities."
Leksell Gamma Knife® delivers very high doses of radiation with minimal
damage to the normal brain tissue surrounding the problem area. It is used for
a variety of neurological disorders, including arteriovenous malformations,
vestibular schwannomas, meningiomas, pituitary tumors, trigeminal neuralgia
and brain metastases. Research is being conducted on other possible uses of
Leksell Gamma Knife®, such as treating epilepsy, Parkinson's disease and
uveal melanoma.
About Elekta
Elekta is an international medical-technology group, providing meaningful
clinical solutions, comprehensive information systems and services for
improved cancer care and management of brain disorders. All of Elekta's
solutions employ non-invasive or minimally invasive techniques and are
therefore clinically effective, gentle on the patient and cost-effective.
Clinical solutions include Leksell Gamma Knife® for non-invasive
treatment of brain disorders and Elekta Synergy® for image guided radiation
therapy (IGRT). Following the acquisition of IMPAC Medical Systems Inc. in
April 2005, the Elekta Group is the world's largest supplier of oncology
software.
Elekta's systems and solutions are used in over 3,000 hospitals around the
world to treat cancer and to manage clinical operations as well as to diagnose
and treat brain disorders, including tumors, vascular malformations and
functional disorders.
With approximately 1,700 employees, Elekta's corporate headquarters is
located in Stockholm, Sweden, and the company is listed on the Stockholm Stock
Exchange under the ticker EKTAb.
Brain Tumors and Disorders
ATLANTA, Aug. 15 /PRNewswire/ -- Radiosurgery is credited with improving
patient quality of life, reducing treatment costs and enhancing clinical
outcomes. Patients undergoing non-invasive Gamma Knife® surgery, which is
completed in a matter of hours, generally go home within 24 hours and resume
normal activities within a few days.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020318/ELEKTALOGO )
More than 220 Gamma Knife® units are in operation worldwide and more
than 350,000 patients have been treated, according to Jim Rose, Vice President
and head of Marketing in North America for Elekta, the system's manufacturer.
"Gamma Knife® surgery remains the most accurate and proven means of
performing brain radiosurgery, and the single most trusted and utilized
solution for treating intracranial disorders without invasive surgery," he
said.
Cedars-Sinai Medical Center, which has been voted the most preferred
hospital in Los Angeles for all health needs for the past 17 years, will soon
add Leksell Gamma Knife® 4C to its Samuel Oschin Comprehensive Cancer
Institute.
This latest-generation system offers a simplified and more efficient
treatment process and enhanced precision through new, integrated image
treatment possibilities. It includes Leksell GammaPlan® 4C planning
software, providing users with a previously unattainable possibility to
integrate images from various image sources and as a result achieve higher
treatment precision and improved treatment results.
"We continually seek more effective means of treating brain tumors," said
Keith L. Black, M.D., Director of the Cedars-Sinai Maxine Dunitz Neurosurgical
Institute and Director of the medical center's Division of Neurosurgery and
Comprehensive Brain Tumor Program. "The efficacy of Gamma Knife® surgery,
documented in over 2,000 peer-reviewed published papers, makes this an
excellent complement to our existing therapies and radiosurgery capabilities."
Leksell Gamma Knife® delivers very high doses of radiation with minimal
damage to the normal brain tissue surrounding the problem area. It is used for
a variety of neurological disorders, including arteriovenous malformations,
vestibular schwannomas, meningiomas, pituitary tumors, trigeminal neuralgia
and brain metastases. Research is being conducted on other possible uses of
Leksell Gamma Knife®, such as treating epilepsy, Parkinson's disease and
uveal melanoma.
About Elekta
Elekta is an international medical-technology group, providing meaningful
clinical solutions, comprehensive information systems and services for
improved cancer care and management of brain disorders. All of Elekta's
solutions employ non-invasive or minimally invasive techniques and are
therefore clinically effective, gentle on the patient and cost-effective.
Clinical solutions include Leksell Gamma Knife® for non-invasive
treatment of brain disorders and Elekta Synergy® for image guided radiation
therapy (IGRT). Following the acquisition of IMPAC Medical Systems Inc. in
April 2005, the Elekta Group is the world's largest supplier of oncology
software.
Elekta's systems and solutions are used in over 3,000 hospitals around the
world to treat cancer and to manage clinical operations as well as to diagnose
and treat brain disorders, including tumors, vascular malformations and
functional disorders.
With approximately 1,700 employees, Elekta's corporate headquarters is
located in Stockholm, Sweden, and the company is listed on the Stockholm Stock
Exchange under the ticker EKTAb.